Dr. Hartung is the interim director of CHOP's Sickle Cell Center and the director of innovation of the CuRED Frontier Program. His clinical focus is on bone marrow failure syndromes and sickle cell disease and his research focus is on entrepreneurial science and medical device development.
Dr. Stallings is working on intervention trials involving three chronic diseases with nutrition-related abnormalities resulting in meaningful adverse outcomes: cystic fibrosis (new drugs), sickle cell disease (vitamin A) and chronic pancreatitis (enzyme replacement drug).
Dr. Shults works to develop statistical methods for longitudinal data that include semi-parametric approaches to account for subject/cluster level associations and maximum likelihood-based approaches for simulation and analysis of discrete longitudinal outcomes that may have overdispersion.
Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.
The research interests of Dr. Allen include lung function testing in children, adolescents, and infants; developmental chest wall physiology; pulmonary complications of sickle cell disease; and complications of cystic fibrosis.
Dr. Benton's research focuses primarily on pediatric mood and anxiety disorders, sickle cell disease and psychiatric conditions, HIV and psychiatric conditions, neuroimmunology and mood disorders, health services research, eating disorders, and ethnically diverse children.